Digipath makes significant strides with GroSciences’ Tru-Hemp ID Kit

Digipath, Inc.(OTCQB: DIGP) an independent testing laboratory, data analytics, and formulation firm specializing in hemp and cannabis, announced Monday that GroSciences, a subsidiary company, has made significant progress in developing its Tru-Hemp ID project.

The company now targets commercial availability as late 2019/early 2020.

Digipath, through GroSciences, has developed a field testing kit for hemp, cannabis, and other related products with a myriad of applications from law enforcement to growers.

The news from GroSciences  comes as they successfully completed in-house testing of the prototype Tru-Hemp ID DNA-based assay kits at two separate laboratories.

   

Tru-Hemp ID was able to distinguish industrial hemp which is legal under the 2018 Farm Bill, from drug-type cannabis.

GroSciences will launch a pilot program to beta-test Tru-Hemp ID in August.

The Beta testing will be conducted in Vermont, New York, and North Carolina, and possible testing in Oregon, Colorado, and California.

“We have made significant progress in developing GroSciences’ molecular assay, Tru-Hemp ID,” stated Chief Science Officer for Digipath, Dr. Cindy Orser. “In addition to developing the technology for the Tru-Hemp ID testing kit, we are partnering with leading hemp growers to conduct independent testing using our technology, which we expect to help accelerate our path to market and commercial acceptance of our testing kit.”

“The deployment of Tru-Hemp ID in the commercial marketplace will provide Digipath with a new revenue stream,” added Todd Denkin, CEO, Digipath. “Our goal is to not just be a leading testing lab, but a leading canna-tech company.”